Back to resultsAssessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 Genotype
Primary Purpose
HIV Infections
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Analytical Treatment Interruption (ATI)
Sponsored by
About this trial
This is an interventional other trial for HIV Infections focused on measuring treatment interruption, HIV remission, Post-treatment control, HLA-B35, Early treatment
Eligibility Criteria
Inclusion Criteria:
- Aged 18 years at the time of consent
- Enrolled and currently followed in the ANRS CO6 PRIMO Cohort
- With the MHC genotype: at least one HLA B35 or B53 allele AND one HLA-A or B allele carrying the Bw4 epitope AND homozygous -21T residue in the HLA-B alleles AND heterozygous or homozygous for C2 epitope-carrying HLA-C alleles
- Treated with cART within 3 months following inclusion in ANRS CO6 Primo Cohort during at least 18 months and cART not modified in the last 3 months
- Controlled on cART: > 90% of VL below the threshold after initial virological response
- All VL below the threshold during the previous 12 months
- Most recent CD4 measurement on cART above 500 cells/mm3
- Written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the study (article L1122-1-1 of the Public Health Code)
- Person affiliated or beneficiary of a social security scheme (article L1121-11 of the Public Health Code) (State Medical Aid or AME is not a social security scheme)
- Patient agreeing to participate in the trial according to the defined procedures.
Exclusion Criteria:
- One VL above 1000 cp/mL on or off antitretrovirals after the initial viral control on antiretrovirals was achieved.
- Patient in whom condom sex use or PrEP use by the partner will be difficult or impossible.
- Woman with a pregnancy project and pregnant woman.
- Patient under guardianship or curatorship.
- History of a clinical AIDS event or cancer.
- Active HCV or HBV infection.
- Any symptoms or laboratory values suggesting a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or other medical conditions, related to HIV or not, which contraindicates the interruption of ARVs.
- Recent SARS-CoV-2 infection and / or associated with a drop in CD4 and / or associated with a resumption of CV in the last 6 months. In this situation, wait until the CD4 has returned to a rate > 500/mm3 and a CV < 50 copies / mL consolidated for > 6 months.
- Affection, disability, resulting from a SARS-CoV-2 infection, regardless of the duration of the SARS-CoV-2 infection.
- Patient participating in another research evaluating other treatments with an exclusion period ongoing at the screening visit.
- Planned absence which could prevent optimal trial participation (vacation abroad, moving, imminent job change ...).
Sites / Locations
- Centre Hospitalier du Pays d'AixRecruiting
- Hôtel Dieu
- Hôpital Avicenne
- Hôpital Saint-André
- Hôpital PELLEGRIN
- Hôpital de la Côte de Nacre
- Hôpital Gabriel Montpied
- Hôpital Le BocageRecruiting
- Hôpital Pierre Zobda-Quitman
- Hôpital Raymond PoincaréRecruiting
- CHD Vendée
- Hôpital de Bicêtre
- Hôpital de la Croix Rousse
- Hôpital Edouard HERRIOT
- Hôpital Sainte Marguerite
- Hôpital Gui de Chauliac
- Hôtel DieuRecruiting
- Hôpital CarémeauRecruiting
- Hôtel Dieu
- La Pitié Salpêtrière
- Institut Pasteur
- Hôpital de l'Hôtel-DieuRecruiting
- Hôpital Lariboisière
- Hôpital Saint-LouisRecruiting
- Hôpital Tenon
- Hôpitaux Universitaires de Strasbourg
- Hôpital de PurpanRecruiting
- Hôpital Gustave DronRecruiting
- Hôpital Bretonneau
- CHI Villeneuve Saint Georges
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Patients treated early and carrying the MHC B35/53Bw4TTC2 Genotype
Arm Description
Patients included in the ANRS CO6 PRIMO cohort, treated early and carrying the MHC B35/53Bw4TTC2 Genotype
Outcomes
Primary Outcome Measures
Proportion of subjects with a Plasma HIV-1 RNA (viral load,VL) below 400 copies/mL at 6 months after Treatment interruption (Week 24).
Proportion of subjects with a Plasma HIV-1 RNA below 400 copies/mL on subjects included at 6 months after Treatment interruption.
Secondary Outcome Measures
The acceptation rate of the trial by eligible patients
Percentage of patients who accept to participate on patients pré-screened and eligible
Proportion of patients with a plasma VL < 50 copies/ml at 3 and 6 months following Analytic Treatment Interruption (ATI)
Proportion of patients with a plasma VL < 50 copies/ml at 3 and 6 months following ATI
Evolution of number of CD4 T cells count during ATI and after ART resumption
Measurement of CD4 T cells count at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption
Evolution of CD4 to CD8 ratio during ATI and after ART resumption
Measurement of CD4 to CD8 at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption
Evolution of total and integrated HIV DNA and cell-associated HIV RNA transcripts
Quantification of total HIV-DNA and integrated HIV-DNA by ultrasensitive techniques (ultrasensitive real-time PCR and Alu PCR) Quantification of intracellular HIV-RNA transcripts by ultrasensitive technique (ultrasensitive qPCR gag).
Evolution of HIV markers in sperm (on 25 participants)
Quantification of HIV DNA on semen cells (ultrasensitive technique) and quantification of HIV RNA on seminal fluid (ultrasensitive technique)
Evolution of the levels of inflammation markers during ATI
Physiological parameters levels will be studied (Luminex and Simoa technology): IFNα, TGFβ, IL-7, IL-12, IL-15, IL-18, IP-10, DPPIV, ARNr 16S, I-FABP, citrulline, sCD14, sCD163
Proportion of patients who resumed treatment during the first 6 months of ATI, according to the reasons for resuming
Percentage of resumption, according to the reasons listed in the protocol, before the evaluation of the primary outcome
Pharmacological dosages of antiretrovirals performed during the ATI from frozen samples
Pharmacological dosages of antiretrovirals performed during the ATI at Week 2 and Week 24 of ATI
Proportion of patients reporting at each visit to use condoms
Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.
Proportion of patients reporting at each visit to have proposed PrEP at their partners
Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.
Proportion of patients satisfied with their participation at the end of the trial
Through statistical analyses of some self-administered questionnaires items (Likert).
On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.
Evolution of the level of the quality of life between inclusion and the end of the trial
Through statistical analyses of some self-administered questionnaires items ( SF12.v2 scale for quality of life). The 12-item Short-Form Health Survey is a widely used, generic patient-reported measure of health status that provides summary scores of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Evolution of the global satisfaction with sexual life between inclusion and the end of the trial
Through statistical analyses of some self-administered questionnaires items (Likert).
On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.
Full Information
NCT ID
NCT05482854
First Posted
January 3, 2022
Last Updated
September 28, 2023
Sponsor
ANRS, Emerging Infectious Diseases
1. Study Identification
Unique Protocol Identification Number
NCT05482854
Brief Title
Assessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 Genotype
Official Title
ANRS 175 RHIVIERA-01: Assessment of HIV Remission Upon Combination Antiretroviral Therapy (cART) Interruption in Early Treated Individuals From ANRS CO6 PRIMO Cohort Carrying the Major Histocompatibility Complex (MHC) B35/53Bw4TTC2 Genotype
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 20, 2023 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
July 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ANRS, Emerging Infectious Diseases
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the trial is to evaluate in ANRS CO6 PRIMO cohort participants if the presence of the MHC B35 (53) Bw4TTC2 genotype favors the control of HIV infection (defined by a viral load (VL) less than 400 cp/mL) after discontinuation of antiretroviral therapy (ART) initiated during primary HIV infection.
The trial will be a pilot "proof of concept", one arm, multicenter, nested in the ANRS CO6 PRIMO Cohort, in which the intervention is treatment interruption (of at least 6 months).
It is planned to include between 20 and 50 participants.
Detailed Description
The ANRS 175 RHIVIERA 01 trial will focus on people who were initiated early and have a particular genotypic profile associated with HIV remission.
The study proposes to test an intervention consisting in a ART-treatment interruption (of at least 6 months) in ANRS CO6 PRIMO cohort participants carrying the MHC B35/53Bw4TTC2 genotype and well controlled on cART.
The study aims to enrol 20-30 participants in 30 French clinical sites. Participants will be enrolled after checking eligibility criteria and will interrupt ART immediatly after inclusion.
Control of HIV-Infection, defined by a viral load less than 400 cp/mL, will be evaluated after 24 weeks of interruption.
Study duration will vary by participant, depending on the time of ART interruption and the time to viral rebound. Participants will be followed maximum 48 weeks on ATI. If there is a viral rebound justifying the resumption of ART, participant will be followed 24 weeks maximum after resumption. The maximum duration of the study will be 48+24 = 72 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
treatment interruption, HIV remission, Post-treatment control, HLA-B35, Early treatment
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
The trial will be a pilot "proof of concept", one arm, multicenter, nested in the ANRS CO6 PRIMO Cohort, in which the intervention is treatment interruption (of at least 6 months).
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients treated early and carrying the MHC B35/53Bw4TTC2 Genotype
Arm Type
Experimental
Arm Description
Patients included in the ANRS CO6 PRIMO cohort, treated early and carrying the MHC B35/53Bw4TTC2 Genotype
Intervention Type
Other
Intervention Name(s)
Analytical Treatment Interruption (ATI)
Intervention Description
Analytical Interruption of Treatment for 24-48 weeks
ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria
Primary Outcome Measure Information:
Title
Proportion of subjects with a Plasma HIV-1 RNA (viral load,VL) below 400 copies/mL at 6 months after Treatment interruption (Week 24).
Description
Proportion of subjects with a Plasma HIV-1 RNA below 400 copies/mL on subjects included at 6 months after Treatment interruption.
Time Frame
Six months after treatment interruption (Week 24).
Secondary Outcome Measure Information:
Title
The acceptation rate of the trial by eligible patients
Description
Percentage of patients who accept to participate on patients pré-screened and eligible
Time Frame
At inclusion (Day 0)
Title
Proportion of patients with a plasma VL < 50 copies/ml at 3 and 6 months following Analytic Treatment Interruption (ATI)
Description
Proportion of patients with a plasma VL < 50 copies/ml at 3 and 6 months following ATI
Time Frame
At 3 months (week 12) and 6 months (week 24) following ATI
Title
Evolution of number of CD4 T cells count during ATI and after ART resumption
Description
Measurement of CD4 T cells count at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption
Time Frame
During all ATI period (from Day 0 to Day 0 ART resumption - maximum 48 weeks) and during ART resumption period (maximum 24 Weeks)
Title
Evolution of CD4 to CD8 ratio during ATI and after ART resumption
Description
Measurement of CD4 to CD8 at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption
Time Frame
During all ATI period (from Day 0 to Day 0 ART resumption - maximum 48 weeks) and during ART resumption period (maximum 24 Weeks)
Title
Evolution of total and integrated HIV DNA and cell-associated HIV RNA transcripts
Description
Quantification of total HIV-DNA and integrated HIV-DNA by ultrasensitive techniques (ultrasensitive real-time PCR and Alu PCR) Quantification of intracellular HIV-RNA transcripts by ultrasensitive technique (ultrasensitive qPCR gag).
Time Frame
During ATI period (At Day 0, Week 4, Week 12, Week 24) and during ART resumption period (at Day 0 Resumption, and Week 24 ART Resumption)
Title
Evolution of HIV markers in sperm (on 25 participants)
Description
Quantification of HIV DNA on semen cells (ultrasensitive technique) and quantification of HIV RNA on seminal fluid (ultrasensitive technique)
Time Frame
During ATI period (At Day 0, Week 4, Week 12, Week 24) and at Day 0 ART resumption
Title
Evolution of the levels of inflammation markers during ATI
Description
Physiological parameters levels will be studied (Luminex and Simoa technology): IFNα, TGFβ, IL-7, IL-12, IL-15, IL-18, IP-10, DPPIV, ARNr 16S, I-FABP, citrulline, sCD14, sCD163
Time Frame
During ATI period (up to week 24 ATI) and at Day 0 ART resumption
Title
Proportion of patients who resumed treatment during the first 6 months of ATI, according to the reasons for resuming
Description
Percentage of resumption, according to the reasons listed in the protocol, before the evaluation of the primary outcome
Time Frame
At week 24
Title
Pharmacological dosages of antiretrovirals performed during the ATI from frozen samples
Description
Pharmacological dosages of antiretrovirals performed during the ATI at Week 2 and Week 24 of ATI
Time Frame
At Week 2 and Week 24 of ATI
Title
Proportion of patients reporting at each visit to use condoms
Description
Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.
Time Frame
From date of inclusion to the last follow-up visit, up to 72 weeks (average of 1 year).
Title
Proportion of patients reporting at each visit to have proposed PrEP at their partners
Description
Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.
Time Frame
From date of inclusion to the last follow-up visit, up to 72 weeks (average of 1 year).
Title
Proportion of patients satisfied with their participation at the end of the trial
Description
Through statistical analyses of some self-administered questionnaires items (Likert).
On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.
Time Frame
Questionnaire at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate)
Title
Evolution of the level of the quality of life between inclusion and the end of the trial
Description
Through statistical analyses of some self-administered questionnaires items ( SF12.v2 scale for quality of life). The 12-item Short-Form Health Survey is a widely used, generic patient-reported measure of health status that provides summary scores of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time Frame
Questionnaire at Day 0, at Week 24 (or resumption of ART) and at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate)
Title
Evolution of the global satisfaction with sexual life between inclusion and the end of the trial
Description
Through statistical analyses of some self-administered questionnaires items (Likert).
On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.
Time Frame
Questionnaire at Day 0, at Week 24 (or resumption of ART) and at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged 18 years at the time of consent
Enrolled and currently followed in a site of the ANRS CO6 PRIMO Cohort
With the MHC genotype: at least one HLA B35 or B53 allele AND one HLA-A or B allele carrying the Bw4 epitope AND homozygous -21T residue in the HLA-B alleles AND heterozygous or homozygous for C2 epitope-carrying HLA-C alleles
Treated with cART within 3 months following inclusion in ANRS CO6 Primo Cohort during at least 18 months and cART not modified in the last 3 months
Controlled on cART: > 90% of VL below 50 cp/mL after initial virological response
All VL below 50 cp/mL during the previous 12 months
Most recent CD4 measurement on cART above 500 cells/mm3
Written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the study (article L1122-1-1 of the Public Health Code)
Person affiliated or beneficiary of a social security scheme (article L1121-11 of the Public Health Code) (State Medical Aid or AME is not a social security scheme)
Patient agreeing to participate in the trial according to the defined procedures.
Exclusion Criteria:
One VL above 1000 cp/mL on or off antitretrovirals after the initial viral control on antiretrovirals was achieved.
Patient on long-acting injectable HIV treatment
Patient in whom condom sex use or PrEP use by the partner will be difficult or impossible.
Woman with a pregnancy project and pregnant woman.
Patient under guardianship or curatorship.
History of a clinical AIDS event or cancer.
Active HCV or HBV infection.
Any symptoms or laboratory values suggesting a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or other medical conditions, related to HIV or not, which contraindicates the interruption of ARVs.
Recent SARS-CoV-2 infection and / or associated with a drop in CD4 and / or associated with a resumption of CV in the last 6 months. In this situation, wait until the CD4 has returned to a rate > 500/mm3 and a CV < 50 copies / mL consolidated for > 6 months.
Affection, disability, resulting from a SARS-CoV-2 infection, regardless of the duration of the SARS-CoV-2 infection.
Patient participating in another research evaluating other treatments with an exclusion period ongoing at the screening visit.
Planned absence which could prevent optimal trial participation (vacation abroad, moving, imminent job change ...).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vincent MEIFFREDY
Phone
00 33 1 45 59 52 06
Email
vincent.meiffredy@inserm.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Nicolas LETURQUE
Phone
00 33 1 45 59 51 93
Email
nicolas.leturque@inserm.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cécile GOUJARD
Organizational Affiliation
Hôpital Bicêtre, Service de médecine interne et d'immunologie clinique
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier du Pays d'Aix
City
Aix-en-Provence
ZIP/Postal Code
13616
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine FAUDON
Email
cfaudon@ch-aix.fr
First Name & Middle Initial & Last Name & Degree
Thierry ALLEGRE, MD
Facility Name
Hôtel Dieu
City
Angers
ZIP/Postal Code
49033
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital Avicenne
City
Bobigny
ZIP/Postal Code
93000
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital Saint-André
City
Bordeaux
ZIP/Postal Code
33075
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital PELLEGRIN
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital de la Côte de Nacre
City
Caen
ZIP/Postal Code
14033
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital Gabriel Montpied
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital Le Bocage
City
Dijon
ZIP/Postal Code
21034
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carole CHARLES
Email
carole.charles@chu-dijon.fr
First Name & Middle Initial & Last Name & Degree
Lionel PIROTH, PhD
Facility Name
Hôpital Pierre Zobda-Quitman
City
Fort De France
ZIP/Postal Code
97261
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital Raymond Poincaré
City
Garches
ZIP/Postal Code
92380
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rezak MAHREZ
Email
rezak.mahrez@aphp.fr
First Name & Middle Initial & Last Name & Degree
Pierre DE TRUCHIS, MD
Facility Name
CHD Vendée
City
La Roche-sur-Yon
ZIP/Postal Code
85925
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital de Bicêtre
City
Le Kremlin-Bicêtre
ZIP/Postal Code
94275
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital de la Croix Rousse
City
Lyon
ZIP/Postal Code
69317
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital Edouard HERRIOT
City
Lyon
ZIP/Postal Code
69437
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital Sainte Marguerite
City
Marseille
ZIP/Postal Code
13274
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital Gui de Chauliac
City
Montpellier
ZIP/Postal Code
34295
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôtel Dieu
City
Nantes
ZIP/Postal Code
44035
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Morane CAVELLEC
Email
Morane.CAVELLEC@chu-nantes.fr
First Name & Middle Initial & Last Name & Degree
François RAFFI, PhD
Facility Name
Hôpital Carémeau
City
Nîmes
ZIP/Postal Code
30029
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Régine DONCESCO
Email
regine.doncesco@chu-nimes.fr
First Name & Middle Initial & Last Name & Degree
Didier LAUREILLARD, MD
Facility Name
Hôtel Dieu
City
Paris
ZIP/Postal Code
75004
Country
France
Individual Site Status
Withdrawn
Facility Name
La Pitié Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France
Individual Site Status
Withdrawn
Facility Name
Institut Pasteur
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital de l'Hôtel-Dieu
City
Paris
ZIP/Postal Code
75181
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Josée DULUCQ
Email
marie-josee.dulucq@aphp.fr
First Name & Middle Initial & Last Name & Degree
Jean-Paul VIARD, PhD
Facility Name
Hôpital Lariboisière
City
Paris
ZIP/Postal Code
75475
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital Saint-Louis
City
Paris
ZIP/Postal Code
75475
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeannine DELGADO
Email
jeannine.delgado@aphp.fr
First Name & Middle Initial & Last Name & Degree
Jean-Michel MOLINA, PhD
Facility Name
Hôpital Tenon
City
Paris
ZIP/Postal Code
75970
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpitaux Universitaires de Strasbourg
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital de Purpan
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sandra LAGARRIGUE
Email
lagarrigue.s@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Pierre DELOBEL, PhD
Facility Name
Hôpital Gustave Dron
City
Tourcoing
ZIP/Postal Code
59027
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pauline CORNAVIN
Email
pcornavin@ch-tourcoing.fr
First Name & Middle Initial & Last Name & Degree
Olivier ROBINEAU, PhD
Facility Name
Hôpital Bretonneau
City
Tours
ZIP/Postal Code
37044
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CHI Villeneuve Saint Georges
City
Villeneuve Saint Georges
ZIP/Postal Code
94195
Country
France
Individual Site Status
Active, not recruiting
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Assessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 Genotype
We'll reach out to this number within 24 hrs